BioSpace News Archive

Endo International plc (NASDAQ:ENDP) announced today initial results from a Phase I study (EN3835–105) evaluating collagenase clostridium histolyticum (CCH) for the treatment of plantar fibromatosis.

Peptilogics announced the appointments of Nikhil Bhide as Chief Business Officer, Dr. Marc Lesnick as SVP Regulatory & Quality, Jodie GiIlon as SVP Corporate Affairs & Patient Advocacy, Albert Fonticiella as VP of People, and Steve Kulp as VP of Operations.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that it will report its second quarter 2021 financial results on Thursday, August 5, 2021, before the opening of the U.S. financial markets.

Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced it has completed enrollment of NEURO-TTRansform, the company’s Phase 3 study of eplontersen, formerly AKCEA-TTR-LRx, for people with hereditary transthyretin-mediated amyloid polyneuropathy.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 associated with progressive decline in renal function.

Seres Therapeutics, Inc., a leading microbiome therapeutics company, announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m. ET to discuss second quarter 2021 results and provide a general business update.

AVEO Oncology, a commercial and clinical development stage biopharmaceutical company, announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T.

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that it will report the Company’s second quarter 2021 financial results and corporate highlights on August 5, 2021 at 7:30 a.m. ET.

Landos Biopharma, Inc (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced financial results for the second quarter ended June 30, 2021 and provided business updates.